Novel mechanisms reshaping the phase 3 pipeline in wet and dry AMD

Currently, anti-VEGF therapy remains the backbone of wet age-related macular degeneration (AMD) treatment, and complement inhibition has defined the first approved therapies for geographic atrophy in dry AMD. Since their entrance to clinical practice, these medication classes have defined the standard for disease management; however, their impact has not resulted in a halting of seeking more innovative approaches to AMD.